Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study
Oncology · 2024
DOI: 10.1159/000542693 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology, 2024. Verfasst von Ogur Karhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harran University Hospital, University of Harran, Şanliurfa, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Proton Pump Inhibitors. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Conflicting evidence exists regarding the concurrent use of cyclin-dependent kinase (CDK) 4/6 inhibitors and proton pump inhibitors (PPIs) in the treatment of breast cancer. This study aimed to investigate whether PPI use interferes with the efficacy of CDK4/6 inhibitors.
Methods
This retrospective, multicenter, real-world study included 205 patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patient data were collected from January 2020 to August 2023. Patients who received either ribociclib or palbociclib, with or without a PPI, were included. Median progression-free survival (mPFS) was estimated using the Kaplan-Meier method, and factors associated with mPFS were analyzed using Cox regression.
Results
Among the patients, 100 received palbociclib and 105 received ribociclib. In the palbociclib group, 40 patients (40%) used a PPI, and 60 (60%) did not. The mPFS was 16.1 months for patients with a PPI versus 22.2 months for those without (p = 0.26). In the ribociclib group, 44 patients used a PPI and 61 did not use a PPI. The median PFS was comparable between patients receiving PPIs and those not receiving PPIs (19.3 months and 20.7 months, respectively). Poor PFS was associated with liver metastasis, brain metastasis, and high Ki-67.
Conclusion
Concomitant use of PPIs with ribociclib or palbociclib did not affect the efficacy of either CDK4/6 inhibitor. PPIs can be administered alongside these medications when clinically indicated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Harran University Hospital, University of Harran, Şanliurfa, Turkey.
- Department of Medical Oncology, Gazi Yasargil Research and Training Hospital, Diyarbakir, Turkey.
- Department of Medical Oncology, Dicle University Hospital, University of Dicle, Diyarbakir, Turkey.
- Department of Medical Oncology, Yuzuncu Yıl University Hospital, University of Yuzuncu Yıl, Van, Turkey.
- Department of Medical Oncology, Mehmet Akif Inan Research and Training Hospital, Şanlıurfa, Turkey.
Zitieren
APA
Karhan, O., İleri, S., Urakçı, Z., Arvas, H., Kılıç, D. K., Sezgin, Y., Erçek, B. M., & Tunç, S. (2024). Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study. Oncology. https://doi.org/10.1159/000542693
Vancouver
Karhan O, İleri S, Urakçı Z, Arvas H, Kılıç DK, Sezgin Y, et al. Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study. Oncology. 2024. doi:10.1159/000542693
BibTeX
@article{Karhan2024,
author = {Karhan, Ogur and İleri, Serdar and Urakçı, Zuhat and Arvas, Hayati and Kılıç, Delyadıl Karakaş and Sezgin, Yasin and Erçek, Berrak Merit and Tunç, Sezai},
title = {Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study},
journal = {Oncology},
year = {2024},
doi = {10.1159/000542693}
}
EUVIMED